Eventide Asset Management’s Privia Health PRVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19M Hold
737,694
0.25% 115
2026
Q1
$15.2M Hold
737,694
0.25% 120
2025
Q4
$17.5M Hold
737,694
0.27% 109
2025
Q3
$18.4M Sell
737,694
-84,754
-10% -$1.82M 0.3% 101
2025
Q2
$18.9M Hold
822,448
0.33% 95
2025
Q1
$18.5M Buy
822,448
+10
+0% +$232 0.37% 88
2024
Q4
$16.1M Hold
822,438
0.29% 106
2024
Q3
$15M Buy
822,438
+746,231
+979% +$14.2M 0.26% 103
2024
Q2
$1.32M Sell
76,207
-923,793
-92% -$16.4M 0.02% 155
2024
Q1
$19.6M Hold
1,000,000
0.31% 97
2023
Q4
$23M Hold
1,000,000
0.38% 78
2023
Q3
$23M Hold
1,000,000
0.41% 71
2023
Q2
$26.1M Hold
1,000,000
0.44% 68
2023
Q1
$27.6M Hold
1,000,000
0.51% 65
2022
Q4
$22.7M Buy
1,000,000
+584,015
+140% +$16.3M 0.45% 71
2022
Q3
$14.2M Buy
415,985
+138,185
+50% +$5.11M 0.28% 90
2022
Q2
$8.09M Buy
+277,800
New +$7.06M 0.17% 105

Other funds holding PRVA

Eventide Asset Management's PRVA Position: Q2 2026 in Review

Eventide Asset Management held its Privia Health (PRVA) position steady in Q2 2026 at 737,694 shares worth $19M. The position accounts for 0.25% of the portfolio, ranked #115.

Eventide Asset Management first reported a position in PRVA in Q2 2022 and has held it in 17 quarters since. The position peaked at $27.6M in Q1 2023. 301 funds tracked by Wall St. Rank hold PRVA as of Q2 2026.

  • Eventide Asset Management held 737,694 shares of Privia Health worth $19M as of Q2 2026.
  • Eventide Asset Management left its Privia Health share count unchanged in Q2 2026.
  • Privia Health made up 0.25% of Eventide Asset Management's portfolio in Q2 2026, its #115 holding.
  • Eventide Asset Management first reported a position in Privia Health in Q2 2022 and has held it in 17 quarters since.
  • Eventide Asset Management's Privia Health position peaked at $27.6M in Q1 2023.
  • 301 funds tracked by Wall St. Rank held Privia Health as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.